Clinical Trial Update: Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated zoledronic acid (Zometa) for bone metastases in lung cancer (including non-small cell and small cell) and was terminated; results were…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases
• Non-small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Zometa (Zoledronic acid)

Snippet

Sponsor: University of Louisville | Conditions: Carcinoma, Non-Small Cell Lung, Carcinoma, Small Cell Lung | Phase 2 | Status: TERMINATED | Results posted: 2017-04-06